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Abstract
Rosai-Dorfman disease (RDD) is a rare, benign histiocytic proliferative disorder primarily occurring in the lymph
nodes. Extranodal disease can occur in skin and soft tissue, central nervous system, gastrointestinal tract, and breast.
Here we present a case of a 55-year-old female with a history of hypertension, hyperlipidemia, and diabetes mellitus
who presented with a ﬁxed solid mass localized to the right medial thigh. Excision revealed S100 and CD 68 positive
scattered lymphoid aggregates and emperipolesis, hallmark molecular and cytopathologic features of RDD. RDD is a
nonmalignant, classically sporadic histiocytosis. Clinical outcome in terms of mortality seems to be favorable in most
cases, however given the benign and slowly progressive nature of the disease, conservative management with observation is typical, with surgical excision recommended for larger lesions. Currently, therapy revolves around surgical and
immunosuppressive treatments, but the optimal diagnostic and therapeutic management of RDD remains to be deﬁned.
Keywords: Rosai-Dorfman disease

1. Background
osai-Dorfman disease (RDD), ﬁrst described
as a distinct clinicopathological entity in 1969,
is a rare non-malignant disorder characterized by
histiocyte proliferation with a prevalence of only 1 in
200,000 in the United States.1,2 The disease predominantly affects children and young adults, with
a slight male predominance, and oftentimes displays a chronic, relapsing course.3,4 Patients typically present with fever, leukocytosis, and painless
cervical lymphadenopathy. Although RDD has a
predilection for the lymph nodes of the head and
neck, any nodal region may be affected, and
furthermore the disease may also present in extranodal locations including the skin and soft tissue,
central nervous system (CNS), gastrointestinal tract,
and breast.5e12 In contrast to nodal RDD, extranodal, cutaneous RDD usually presents as slowgrowing, painless, nonpruritic nodules, plaques, or

R

papules with coloration varying from yellow to red
to brown.13 Emperipolesis, histiocytic phagocytosis
of lymphocytes, plasma cells, erythrocytes, or polymorphonuclear leukocyte, is considered to be
pathognomonic and remains a critical histopathological feature, along with S-100 and CD68 positive
staining of the histiophagocytic cells.1,14e16 We
present a rare case of Rosai-Dorfmann disease, an
underrecognized and diagnosed entity with limited,
albeit emerging diagnostic criteria, heretofore
focused on immunohistochemistry of tissue samples. We also explore management options, highlighting both conservative evaluation as well as
surgical intervention with periodic surveillance for
resolution or recurrence.

2. Case presentation
A 55-year-old woman with a past medical history
signiﬁcant for hypertension, hyperlipidemia, noninsulin dependent diabetes mellitus, and right
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middle cerebral artery infarction managed with
mechanical thrombectomy presented with complaints of right thigh swelling. She reported usual
health until six months prior to presentation when
she noticed a solid mass on the medial aspect of her
right thigh. There was no associated pain, redness,
or discharge, and no antecedent trauma. Physical
examination demonstrated an 11  6 cm ﬁxed solid
mass localized to the right medial thigh without
erythema, crepitus, or ecchymoses. Diagnostic
evaluation demonstrated unremarkable serum
chemistries. She underwent surgical resection of the
mass with gross examination notable for a tan-yellow lesion measuring 6.1  4.8  2.5 cm surrounded
by normal subcutaneous tissue. Tissue pathology
demonstrated diffuse, sheet-like proliferation of
spindled and epithelioid cells in a background of
sclerotic and ﬁbrotic stroma (Fig. 1). Histological
analysis revealed involvement of mature adipose
tissue and chronic inﬂammation with the presence
of scattered lymphoid aggregates and plasma cells
along with histiocytes containing ample eosinophilic
granular cytoplasm and intact intracytoplasmic inﬂammatory cells (“emperipolesis”) (Fig. 2). Immunohistochemical staining was negative for CD34,
actin, desmin, beta-catenin, CD1a, and mycobacterial/fungal stains, but notably positive for S100
(Fig. 3) and CD68, further conﬁrming the diagnosis.
The patient's wound was, while large, was closed by
primary intention, without tension. She was followed weekly on an outpatient basis with appropriate approximation and closure. She was followed

Fig. 1. Hematoxylin and Eosin staining. At low power magniﬁcation,
sheets and syncytial clusters of histiocytes with abundant pink cytoplasm are admixed with subcutaneous fat (clear spaces, top left and
bottom left corners). Histiocytes containing numerous lymphocytes can
be seen within the cytoplasm of the histiocytes (right side of image), a
histopathologic feature known as “emperipolesis,” the presence of an
intact cell within the cytoplasm of another cell.
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Fig. 2. Hematoxylin and Eosin staining. At higher power, emperipolesis
can be better appreciated. This image contains two histiocytes with
numerous lymphocytes (seen as blue circles with clear halos in this
image) passing through their pink cytoplasm. Emperipolesis, when seen,
is pathognomonic for an underlying diagnosis of Rosai-Dorfman
Disease.

for 6 months, at the time of this report, with no
evidence of local recurrence or dehiscence.

3. Discussion
Rosai-Dorfman disease is a rare, benign, idiopathic
proliferative disorder affecting histiocytes,1 typically
affecting isolated lymph nodes.17e19 Patients present
with bilateral, painless, cervical lymphadenopathy
with or without constitutional symptoms such as
fever, night sweats, and weight loss. Although classically conﬁned to lymph nodes, up to 40% of patients
with RDD manifest extra nodal involvement with or

Fig. 3. S-100 Immunostaining. S-100 is an immunostain that is positive
in histiocytes and can help highlight emperipolesis. Here, we see S-100
highlighting the cell membrane of the histiocytes, which is negative in
the cytoplasmic lymphocytes, another classic histologic ﬁnding in
Rosai-Dorfman Disease.
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without adenopathy. In contrast to nodal disease,
extranodal disease most commonly presents as a
painless, palpable mass. It affects females more
frequently, with one case series documenting a 90%
female predominance.20,21 The most frequent extranodal sites were found to be skin and soft tissue
(16%); nasal cavity and paranasal sinuses (16%); eye,
orbit, and ocular adnexa (11%); bone (11%); salivary
gland (7%); central nervous system (7%); oral cavity
(4%); kidney and genitourinary tract (3%); respiratory tract (3%); liver (1%); tonsil (1%); and breast
(<1%).17 Our patient's presentation correlates well
with previously reported cases of extranodal RDD,
presenting with an insidious, slowly progressing,
asymptomatic mass. While the majority of RDD is
considered to be nodal in nature, an extensive
physical evaluation was performed, yet failed to
demonstrate any evidence of lymphatic swelling.
While some patients with RDD have adjunctive
constitutional symptoms e fever, night sweats,
weight loss e this is not considered to be exclusive
and may raise the specter of an alternative diagnosis
such as a lymphoproliferative disease. Our patient
did not experience any of these symptoms and our
suspicion for an alternative diagnosis, prior to histological sampling, remained low.
The presence of nonspeciﬁc symptoms such as
fever, leukocytosis, weight loss, and cervical lymphadenopathy in individuals with RDD may mimic a
variety of lymphoproliferative disorders: Hodgkin's
and non-Hodgkin's lymphoma, Langerhans cell
histiocytosis, granulomatous lymphadenitis, reactive
lymphadenopathy, Castleman's Disease, and Kikuchi-Fujimoto disease e making histopathology a key
feature of diagnosis.22 Histologically, RDD is characterized not only by histiocytic proliferation, but
also histiocyte-mediated phagocytosis of intact lymphocytes and other immune cells, leading to the
disease's histological hallmark ﬁnding, emperipolesis.23 These histiocytes are typically positive for S100 and CD68 antigens and negative for CD1a
immunohistochemical staining and BRAF V600E
mutations.24,25 These ﬁndings are used to differentiate RDD from Langerhans's cell histiocytosis and
Erdheim-Chester Disease, in which the histopathological ﬁndings are characterized by a lack of
emperipolesis and the presence of Langerhans' cells
and foamy histiocytes.26e28 Furthermore, these disorders appear to have unique immunohistochemical
signatures: S100-negative, CD68-positive, CD1a
negative, and BRAF V600E positive cells in ErdheimChester; S100-positive, CD68-positive, CD1a positive, and BRAF V600E positive cells in Langerhans's
cell histiocytosis.

The pathogenesis of RDD remains unknown.
Infection by human herpes virus-6 (HHV-6),
EpsteineBarr virus (EBV), and Parvovirus B19 have
been suspected as instigating events.29e32 Several
genetic mutations have also been identiﬁed recently
including mutations in ARAF,33 MAP2K1,34,35 NRAS,
and KRAS.33 KRAS and MAP2K1 are associated with
33% of RDD cases, suggesting that the RASMAP2K1 pathway may be an integral component of
disease development and thus a potential therapeutic target.36
Of note, our patient had an initial breast biopsy
demonstrating CD68-positive cells, which while not
speciﬁc, could have raised suspicion for extranodal,
breast RDD, speciﬁcally if additional staining for S100 (positive) and the absence of a BRAF V600E
mutation were noted. However, at the time she was
diagnosed with benign histiocytic inﬁltration without
further follow up. While likely unrelated, RDD of the
breast may mimic fat necrosis on core biopsy.37 She
subsequently presented with soft tissue swelling on
the medial aspect of the thigh, which was removed
surgically with subsequent histopathological ﬁndings consistent with RDD. Review of cases with RDD
involving the CNS show a 15% recurrence rate after
surgery,38 though no literature has been reported
regarding recurrence of cutaneous RDD.
The diagnostic and staging evaluation of patients
with newly diagnosed RDD should include an
assessment of disease extent, as well as evaluation
for conditions either known to be associated with
RDD, particularly autoimmune disorders, or known
to contain a component of reactive histiocytosis.39
CT of the neck, chest, abdomen, and pelvis is recommended. RDD lesions are known to be FDGavid, including extra nodal areas40 and FDG-PET/
CT is used by some investigators for initial staging
when possible.41 Biopsy is required for conﬁrmatory
diagnosis.
RDD resolves spontaneously in approximately
20%e50% of the cases,29,42 however a minority of
patients may develop organ dysfunction due to
massive nodal enlargement resulting in fatal disease. Treatment is warranted to halt the natural
progression of RDD in such cases. Therapeutic options for RDD include corticosteroid therapy, surgery, radiation therapy and biologics.44 The natural
history of the disease is uncertain, however, the
reported mortality rate is about 7%; with concomitant presence of immune dysfunction.42e44
Emerging data suggests that given the low rate of
mortality, even in the absence of intervention, more
patients are electing conservative management with
observation as opposed to surgical excision45;

however given that our patient had a large mass,
surgical excision was the treatment of choice.

4. Conclusion
Rosai-Dorfman Disease is a rare, benign histoproliferative disease mainly affecting the lymph
nodes of the head and neck, however the disease
may manifest in alternative lymphatic groups as
well as extranodal sites, including the skin. Conﬁrmatory diagnosis is done by biopsy with histopathological and immunostaining, with classic
demonstration of histiocytic proliferation, histiocyte-mediated phagocytosis of intact lymphocytes
and other immune cells, and positive staining for S100 and CD68 antigens. While the disease may
resolve spontaneously, surgical excision is recommended for larger tumor burden.
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